Helixmith Co Ltd
KOSDAQ:084990
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Helixmith Co Ltd
Additional Paid In Capital
Helixmith Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Helixmith Co Ltd
KOSDAQ:084990
|
Additional Paid In Capital
₩596.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
22%
|
|
|
Celltrion Inc
KRX:068270
|
Additional Paid In Capital
₩14.2T
|
CAGR 3-Years
154%
|
CAGR 5-Years
77%
|
CAGR 10-Years
36%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Additional Paid In Capital
₩323.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Additional Paid In Capital
₩241.6B
|
CAGR 3-Years
40%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Additional Paid In Capital
₩149.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
18%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Additional Paid In Capital
₩543B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Helixmith Co Ltd
Glance View
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
See Also
What is Helixmith Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
596.1B
KRW
Based on the financial report for Dec 31, 2025, Helixmith Co Ltd's Additional Paid In Capital amounts to 596.1B KRW.
What is Helixmith Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
22%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Helixmith Co Ltd have been 1% over the past three years , 2% over the past five years , and 22% over the past ten years .
